Baby Formula Associated with Childhood Leukemia

This week at a meeting of the American Association for Cancer Research Frontiers in Cancer Prevention Research, University of Texas graduate student Jeremy Schaw presented findings from a study which suggest that for every month an infant received formula feeding, that infant's odds of developing pediatric acute lymphoblastic leukemia (ALL) went up.

To reach this conclusion, Schaw and his colleagues studied 142 children with ALL ranging in age from less than a year up to 14, and compared them with matched controls of 284 children. The study focused on various aspects of formula feeding, breastfeeding, and introduction of solid foods as well as their relationship with ALL.

An additional month of formula feeding was found to be associated with a 16% increase in the relative risk of ALL compared with the controls. Every additional month of delay in the start of solid foods increased the odds by 14%.

"One explanation for this co-risk may be that it's the same effect being picked up twice," said Schaw. "Children being given solid foods later may be receiving formula longer."

ALL is the most commonly diagnosed cancer in children. This is not the first study to hint at an association between infant feeding practices and ALL development.

Source: Med Page Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap